Renal disease News and Research

RSS

New biomarkers can predict risk of kidney failure in patients with diabetes

Scientists at Joslin Diabetes Center have identified two novel markers that, when elevated in the blood stream, can predict accurately the risk of renal (kidney) failure in patients with Type 1 and Type 2 diabetes.

20 Jan 2012

Study examines effect of MELD score-based allocation on post-liver transplant kidney failure

Research from the University of Michigan Health System shows the risk for kidney failure among liver transplant recipients is higher following the implementation of Model of End Stage Liver Disease (MELD), a policy change in 2002 that altered how liver transplant allocation is decided.

18 Jan 2012

Many seniors with kidney disease are good candidates for transplants

Thousands more American senior citizens with kidney disease are good candidates for transplants and could get them if physicians would get past outdated medical biases and put them on transplant waiting lists, according to a new study by Johns Hopkins researchers.

13 Jan 2012

KAI commences enrollment in KAI-4169 second Phase 2 study for CKD-MBD

KAI Pharmaceuticals, Inc., a privately held drug discovery and development company, today announced initiation of patient enrollment in the second Phase 2 study of KAI-4169, a novel pharmaceutical agent being tested for the treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD) in hemodialysis patients with secondary hyperparathyroidism (SHPT), which is a frequent and serious complication of end-stage renal disease.

6 Jan 2012

Pharmalink raises SEK 35 million to further advance Nefecon and Busulipo

Pharmalink AB, today announces it has raised SEK 35 million through a rights issue of new shares to the Company's existing shareholders, including Industrifonden.

4 Jan 2012

The Academy of Nutrition and Dietetics to expand coverage of MNT

The Academy of Nutrition and Dietetics has prepared a request to submit to the Centers for Medicare and Medicaid Services (CMS) to expand coverage of medical nutrition therapy (MNT) for specific diseases, including hypertension, obesity, and cancer, as part of the CMS National Coverage Determination (NCD) Process.

19 Dec 2011

Historical context: The intersection of politics and Medicare policy

The 1920s-era charge that national health insurance was socialist eventually begat Ronald Reagan's 1961 anti-Medicare record album. A 1972 carve-out won special Medicare treatment for patients with end-stage renal disease.

16 Dec 2011

Certain measures of kidney health may predict who is likely to die prematurely

Certain measures of kidney health may predict who is likely to die prematurely, according to a study appearing in an upcoming issue of the Journal of the American Society Nephrology.

16 Dec 2011

Statins linked with reduced risk of death among hospitalized flu patients

The two main ways to prevent and control influenza today are annual immunization and antiviral drugs. A team of investigators has found that statins, cholesterol-lowering drugs, may offer an additional treatment to complement these approaches and reduce mortality among patients hospitalized with influenza.

14 Dec 2011

Relaxin improves poor blood flow and kidney function in a rat model of PKD

After a four-week course of the vasodilator hormone relaxin, kidney function and blood flow immediately improved in lab rats genetically altered to model polycystic kidney disease (PKD), a life-threatening genetic disorder, according to research presented on Dec. 6 at the American Society for Cell Biology Annual Meeting in Denver.

7 Dec 2011

Spectrum seeks FDA IND approval for SPI-014 to treat hyperphosphatemia

Spectrum Pharmaceuticals today announced that it has submitted an investigational new drug (IND) application to the U.S. Food & Drug Administration for SPI-014 (previously referred to as RENAZORB), a second-generation lanthanum-based nanoparticle phosphate binding agent, that has the potential to treat hyperphosphatemia in patients with Stage 5 chronic kidney disease, or end-stage renal disease (ESRD).

5 Dec 2011

Diaverum signs joint venture agreement with Nazer Group

November 2011: Diaverum, one of the world´s largest independent renal care providers, has signed a joint venture agreement with Nazer Group, a Saudi Arabian Holding Company with major investments in the medical sector including Bupa Arabia.

22 Nov 2011

American Access Care sold to to Fresenius Medical Care

TA Associates, a leading global growth private equity firm, today announced the sale of its portfolio company American Access Care (AAC) to Fresenius Medical Care AG & Co. KGaA.

7 Nov 2011

Patients with lupus nephritis ESRD choose hemodialysis as initial therapy

Newly published research shows that more patients with end-stage renal disease (ESRD) caused by lupus nephritis choose hemodialysis as their initial kidney replacement therapy over peritoneal dialysis and preemptive kidney transplantation.

7 Nov 2011

Arginase-2 enzyme plays a major role in diabetic nephropathy

The enzyme arginase-2 plays a major role in kidney failure, and blocking the action of this enzyme might lead to protection against renal disease in diabetes, according to researchers.

5 Nov 2011

Exercise, vegetarian diet reduce risk of diabetes in African Americans

New research shows that following a vegetarian diet and exercising at least three times a week significantly reduced the risk of diabetes in African Americans, who are twice as likely to be diagnosed with diabetes when compared to non-Hispanic whites.

4 Nov 2011

Merck’s cholesterol lowering drug gets FDA panel’s vote

A health advisors’ panel have unanimously backed the use of Merck & Co's cholesterol-lowering drug Vytorin for preventing stroke and other heart problems in patients with chronic kidney disease, but only in those patients not yet on dialysis. The panel voted 16-0 during a meeting today in Silver Spring, Maryland.

3 Nov 2011

FDA EMDAC votes to recommend approval of Merck's VYTORIN for pre-dialysis CKD

Merck, known as MSD outside the United States and Canada, announced today that the Endocrinologic and Metabolic Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) unanimously voted to recommend approval of Merck's VYTORIN (ezetimibe/simvastatin) for use in patients with pre-dialysis chronic kidney disease.

3 Nov 2011

Medicare fee payments for outpatient care to go up 1.9 percent; payments for home health will drop

Hospital operators such as Tenet Healthcare Corp. (THC) will get higher federal payments for emergency room visits, diagnostic imaging and other outpatient services in 2012 under U.S. rules. Medicare payments for outpatient services will rise 1.9 percent to $41 billion and dialysis clinics, cancer centers and ambulatory surgery facilities also are scheduled to receive modest fee increases from the U.S. health program for the elderly and disabled under regulations issued yesterday.

3 Nov 2011

HHS issues regs to reduce red tape for hospitals, providers

The Obama administration moved Tuesday to roll back numerous rules that apply to hospitals and other health care providers after concluding that the standards were obsolete or overly burdensome to the industry. Kathleen Sebelius, the secretary of health and human services, said the proposed changes, which would apply to more than 6,000 hospitals, would save providers nearly $1.1 billion a year without creating any "consequential risks for patients."

20 Oct 2011